Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has earned an average rating of “Buy” from the ten research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $9.62.

A number of research firms have recently commented on AUPH. Vetr downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 price objective for the company. in a report on Monday, July 31st. Zacks Investment Research raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Tuesday, August 15th. Cantor Fitzgerald set a $14.00 target price on Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 11th. Finally, BidaskClub cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th.

Several institutional investors have recently added to or reduced their stakes in AUPH. Bank of New York Mellon Corp raised its stake in shares of Aurinia Pharmaceuticals by 1.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 81,950 shares of the biotechnology company’s stock valued at $502,000 after acquiring an additional 931 shares during the period. Royal Bank of Canada lifted its holdings in shares of Aurinia Pharmaceuticals by 8.6% during the 2nd quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 1,341 shares in the last quarter. Nicholas Investment Partners LP boosted its position in Aurinia Pharmaceuticals by 1.0% during the 2nd quarter. Nicholas Investment Partners LP now owns 254,084 shares of the biotechnology company’s stock worth $1,557,000 after purchasing an additional 2,484 shares during the period. UBS Group AG boosted its position in Aurinia Pharmaceuticals by 13.6% during the 1st quarter. UBS Group AG now owns 112,314 shares of the biotechnology company’s stock worth $824,000 after purchasing an additional 13,405 shares during the period. Finally, FMR LLC boosted its position in Aurinia Pharmaceuticals by 0.3% during the 2nd quarter. FMR LLC now owns 5,867,800 shares of the biotechnology company’s stock worth $35,969,000 after purchasing an additional 19,200 shares during the period. 27.76% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals (NASDAQ AUPH) opened at 6.33 on Wednesday. Aurinia Pharmaceuticals has a one year low of $2.02 and a one year high of $10.54. The company’s 50-day moving average price is $6.29 and its 200-day moving average price is $6.62. The stock’s market capitalization is $338.20 million.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.10. The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. Equities research analysts predict that Aurinia Pharmaceuticals will post ($0.94) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/04/aurinia-pharmaceuticals-inc-auph-given-consensus-recommendation-of-buy-by-brokerages.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.